Citation: J. Oger et M. Freedman, Consensus statement of the Canadian MS clinics network on: The use of disease modifying agents in multiple sclerosis, CAN J NEUR, 26(4), 1999, pp. 274-274
Authors:
Koziol, JA
Lucero, A
Sipe, JC
Romine, JS
Beutler, E
Citation: Ja. Koziol et al., Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial, CAN J NEUR, 26(4), 1999, pp. 283-289
Authors:
Huang, ZG
Xue, D
Preston, E
Karbalai, H
Buchan, AM
Citation: Zg. Huang et al., Biphasic opening of the blood-brain barrier following transient focal ischemia: Effects of hypothermia, CAN J NEUR, 26(4), 1999, pp. 298-304
Citation: W. Wang et Rjb. Macaulay, Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines, CAN J NEUR, 26(4), 1999, pp. 305-310
Citation: Jn. Scott et al., Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), CAN J NEUR, 26(4), 1999, pp. 311-312
Citation: Rb. Taylor et al., Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma, CAN J NEUR, 26(4), 1999, pp. 317-320
Citation: A. Hoke et al., Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: Quantitative EMG studies, CAN J NEUR, 26(4), 1999, pp. 325-329